| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5620 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2898 | 2020 |
| Global distribution and prevalence of hepatitis C virus genotypes JP Messina, I Humphreys, A Flaxman, A Brown, GS Cooke, OG Pybus, ... Hepatology 61 (1), 77-87, 2015 | 2212 | 2015 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1762 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1401 | 2021 |
| Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Y Peng, AJ Mentzer, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai, ... Nature immunology 21 (11), 1336-1345, 2020 | 1266 | 2020 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1186 | 2021 |
| Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis ACJ Windsor, S Kanwar, AGK Li, E Barnes, JA Guthrie, JI Spark, F Welsh, ... Gut 42 (3), 431-435, 1998 | 1058 | 1998 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 990 | 2022 |
| Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 781 | 2021 |
| Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease NR West, AN Hegazy, BMJ Owens, SJ Bullers, B Linggi, S Buonocore, ... Nature medicine 23 (5), 579-589, 2017 | 728 | 2017 |
| Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 679 | 2021 |
| Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc, D Zhou, HM Ginn, ... Cell 185 (14), 2422-2433. e13, 2022 | 674 | 2022 |
| Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease R Banerjee, M Pavlides, EM Tunnicliffe, SK Piechnik, N Sarania, R Philips, ... Journal of hepatology 60 (1), 69-77, 2014 | 588 | 2014 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... The lancet Gastroenterology & hepatology 4 (2), 135-184, 2019 | 525 | 2019 |
| Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study T Marjot, AM Moon, JA Cook, S Abd-Elsalam, C Aloman, MJ Armstrong, ... Journal of hepatology 74 (3), 567-577, 2021 | 524 | 2021 |
| Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man E Barnes, A Folgori, S Capone, L Swadling, S Aston, A Kurioka, J Meyer, ... Science translational medicine 4 (115), 115ra1-115ra1, 2012 | 517 | 2012 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 508 | 2021 |
| MAIT cells are activated during human viral infections B Van Wilgenburg, I Scherwitzl, EC Hutchinson, T Leng, A Kurioka, ... Nature communications 7 (1), 11653, 2016 | 504 | 2016 |
| Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties E Billerbeck, YH Kang, L Walker, H Lockstone, S Grafmueller, V Fleming, ... Proceedings of the National Academy of Sciences 107 (7), 3006-3011, 2010 | 429 | 2010 |
M. Azim AnsariOxford Universityndm.ox.ac.uk의 이메일 확인됨
